| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 28, 2026, Jennifer L. Davis, a Class II director of AbbVie Inc. (“AbbVie”), notified the Company’s Board of Directors (the “Board”), of her intent to resign from the Board, effective November 2, 2026, in light of her recent ap... |
| 30 Oct 2026 |
8-K: Results of Operations and Financial Condition
NORTH CHICAGO, Ill., October 30, 2026 – AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2026. |
| 15 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 14, 2026, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director. Dr. Carethers currently serves ... |
| 05 Oct 2026 |
8-K: Results of Operations and Financial Condition
a The Company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2026, as both cannot be reliably forecasted. |
| 03 Sep 2026 |
8-K: Regulation FD Disclosure
Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases |
| 18 Aug 2026 |
8-K: Other Events
SUPPLEMENTAL INDENTURE NO. 13, dated as of August 18, 2026 (this “Supplemental Indenture”), by and between ABBVIE INC., a Delaware corporation (the “Company”) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking associat... |
| 05 Aug 2026 |
8-K: Other Events
AbbVie Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and SG Americas Securities, LLC (together, the “Representatives”) and the othe... |
| 31 Jul 2026 |
8-K: Results of Operations and Financial Condition
NORTH CHICAGO, Ill., July 31, 2026 – AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2026. |
| 06 Jul 2026 |
8-K: Results of Operations and Financial Condition
a The Company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2026, as both cannot be reliably forecasted. |
| 22 Jun 2026 |
8-K: Regulation FD Disclosure
Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseases |
| 12 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
AbbVie held its 2026 Annual Meeting of Stockholders on May 8, 2026. The following is a summary of the matters voted on at that meeting. |
| 29 Apr 2026 |
8-K: Results of Operations and Financial Condition
NORTH CHICAGO, Ill., April 29, 2026 – AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2026. |
| 03 Apr 2026 |
8-K: Results of Operations and Financial Condition
a The Company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the first quarter of 2026, as both cannot be reliably forecasted. |
| 04 Mar 2026 |
8-K: Other Events
SUPPLEMENTAL INDENTURE NO. 12, dated as of March 4, 2026 (this “Supplemental Indenture”), by and between ABBVIE INC., a Delaware corporation (the “Company”) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking associatio... |
| 26 Feb 2026 |
8-K: Other Events
AbbVie Inc., a Delaware corporation (the “Company”), proposes to issue and sell to J.P. Morgan Securities LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC (together, the “Representatives”) and the othe... |
| 04 Feb 2026 |
8-K: Results of Operations and Financial Condition
NORTH CHICAGO, Ill., February 4, 2026 – AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2025. |
| 07 Jan 2026 |
8-K: Results of Operations and Financial Condition
Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2025 are expected to include acquired IPR&D and milestones expense of $1.3 billion on a pre-tax basis, representing an unfavorable impact of $0.71 to both GA... |
| 31 Oct 2025 |
8-K: Results of Operations and Financial Condition
NORTH CHICAGO, Ill., October 31, 2025 – AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2025. |
| 03 Oct 2025 |
8-K: Results of Operations and Financial Condition
a The Company's 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2025, as both cannot be reliably forecasted. |
| 11 Sep 2025 |
8-K: Regulation FD Disclosure
On September 11, 2025, AbbVie announced that it has settled litigation with all generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration for generic versions of upadacitinib tablets, w... |
Loading...